IP Library Granted Patent US 8,461,125
Granted Patent B2
US 8,461,125 · App. 12/856,130 · Granted Jun 11, 2013

Compositions and methods to treat asthma

Inventor: Michael M. Grunstein (Merion Station, PA)
Assignee: The Children's Hospital of Philadelphia
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,461,125
App. No.
12/856,130
Granted
Jun 11, 2013
Kind
B2
Abstract

The present invention provides compositions and methods for the treatment of asthma. The compositions can be, for example, siRNA directed to CD23. The invention also provides a method of treating asthma with a formulation for in vivo delivery of a CD23 siRNA to inhibit IgE binding in a patient.

Claims (9)

1. A method of inhibiting the expression of CD23 in a patient in need thereof comprising administering to the pulmonary system of said patient an effective amount of siRNA molecules comprising a mixture of SEQ ID NO: 3-SEQ ID NO: 10 that direct cleavage of a target CD23 mRNA sequence present in said patient thereby effecting said inhibition.

2. The method of claim 1 , wherein said siRNA molecules are introduced directly into said patient.

3. The method of claim 2 , wherein said siRNA molecules are aerosolized for delivery.

4. The method of claim 2 , wherein said patient is a human.

5. The method of claim 4 , wherein said human is a patient suffering from asthma and said siRNA molecules are administered to treat said asthma.

6. The method of claim 5 , further comprising the administration of at least one anti-inflammatory agent selected from the group consisting of steroidal anti-inflammatory agents and non-steroidal anti-inflammatory agents.

7. The method of claim 6 , wherein said at least one steroidal anti-inflammatory agent is selected from the group consisting of dexamethasone, beclomethasone, fluticasone, triamcinolone and budesonide.

8. The method of claim 6 , wherein said at least one non-steroidal anti-inflammatory agent is selected from the group consisting of IgE inhibitors, phosphodiesterase inhibitors, methylxanthines, leukotriene modifiers, anti-cholinergic agents, and beta-adrenergic agents.

9. The method of claim 6 , wherein said at least one non-steroidal anti-inflammatory agent is selected from the group consisting of indomethacin, ibuprofen, naproxen, diclofenac, sulindac, oxaprozin, diflunisal, bromfenac, piroxicam, etodolac, fenoprofen, and sodium cromolyn.

Assignments (3)
CONFIRMATORY LICENSE Recorded Oct 11, 2016
From: CHILDREN'S HOSP OF PHILADELPHIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 039981/0202 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 19, 2012
From: GRUNSTEIN, MICHAEL
To: THE CHILDREN'S HOSPITAL OF PHILADELPHIA
Reel/Frame 027560/0100 →
CONFIRMATORY LICENSE Recorded Oct 13, 2010
From: CHILDREN'S HOSPITAL OF PHILADEPHIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 025130/0551 →
Continuity (3)
Continuation In Part PCTUS2009034300 · Feb 17, 2009
Provisional Application 61028699 · Feb 14, 2008
Related Publication 20110014133A1 · Jan 20, 2011